TY - JOUR
T1 - The benefits and challenges associated with the use of drug delivery systems in cancer therapy
AU - Cukierman, Edna
AU - Khan, David R.
N1 - Copyright 2010 Elsevier Inc. All rights reserved.
PY - 2010/9
Y1 - 2010/9
N2 - The use of drug delivery systems as nanocarriers for chemotherapeutic agents can improve the pharmacological properties of drugs by altering drug pharmacokinetics and biodistribution. Among the many drug delivery systems available, both micelles and liposomes have gained the most attention in recent years due to their clinical success. There are several formulations of these nanocarrier systems in various stages of clinical trials, as well as currently clinically approved liposomal-based drugs. In this review, we discuss these drug carrier systems, as well as current efforts that are being made in order to further improve their delivery efficacy through the incorporation of targeting ligands. In addition, this review discusses aspects of drug resistance attributed to the remodeling of the extracellular matrix that occurs during tumor development and progression, as well as to the acidic, hypoxic, and glucose-deprived tumor microenvironment. Finally, we address future prospective approaches to overcoming drug resistance by further modifications made to these drug delivery systems, as well as the possibility of coencapsulation/coadministration of various drugs aimed to surmount some of these microenvironmental-influenced obstacles for efficacious drug delivery in chemotherapy.
AB - The use of drug delivery systems as nanocarriers for chemotherapeutic agents can improve the pharmacological properties of drugs by altering drug pharmacokinetics and biodistribution. Among the many drug delivery systems available, both micelles and liposomes have gained the most attention in recent years due to their clinical success. There are several formulations of these nanocarrier systems in various stages of clinical trials, as well as currently clinically approved liposomal-based drugs. In this review, we discuss these drug carrier systems, as well as current efforts that are being made in order to further improve their delivery efficacy through the incorporation of targeting ligands. In addition, this review discusses aspects of drug resistance attributed to the remodeling of the extracellular matrix that occurs during tumor development and progression, as well as to the acidic, hypoxic, and glucose-deprived tumor microenvironment. Finally, we address future prospective approaches to overcoming drug resistance by further modifications made to these drug delivery systems, as well as the possibility of coencapsulation/coadministration of various drugs aimed to surmount some of these microenvironmental-influenced obstacles for efficacious drug delivery in chemotherapy.
KW - Chemotherapy
KW - Drug delivery
KW - Extracellular matrix
KW - Liposomes
KW - Micelles
KW - Nanocarriers
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=77954215975&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2010.04.020
DO - 10.1016/j.bcp.2010.04.020
M3 - Review article
C2 - 20417189
SN - 0006-2952
VL - 80
SP - 762
EP - 770
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 5
ER -